Journal Mobile Options
Table of Contents
Vol. 58, No. 3-4, 2008
Issue release date: March 2009

Cognitive Performance and Grey Matter Density in Psychosis: Functional Relevance of a Structural Endophenotype

Habets P. · Krabbendam L. · Hofman P. · Suckling J. · Oderwald F. · Bullmore E. · Woodruff P. · Van Os J. · Marcelis M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Structural brain changes and cognitive impairments have been identified as indicators of genetic risk for schizophrenia. However, the pattern of associations between such structural and functional liability markers has been less well investigated. Methods: Magnetic resonance imaging data and cognitive assessments were acquired in 31 patients with psychosis, 32 non-psychotic first-degree relatives and 28 controls. The relationship between cerebral grey matter density and cognitive performance was examined using computational morphometry. Results: Two out of 6 cognitive tests revealed significant associations with grey matter density in regions of the frontal lobe, basal ganglia, thalamus and cerebellum in patients and relatives. In patients, poorer executive functioning was associated with cerebellar grey matter density deficits. In relatives, poorer executive functioning was associated with increased grey matter density in the cerebellum and frontal lobe. In both patients and relatives, strategic retrieval from semantic memory was positively associated with grey matter density in basal ganglia structures. Some additional negative associations in the patients differentiated this group from relatives. Conclusions: The overlap in structure-function relationships in individuals with schizophrenia and those with liability for the disorder may suggest that regional grey matter density alterations functionally alter particular neurocircuits, which could lead to cognitive deficits. The non-overlapping structure-function correlations may reflect disease-related or compensatory mechanisms.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Keshavan MS, Prasad KM, Pearlson G: Are brain structural abnormalities useful as endophenotypes in schizophrenia? Int Rev Psychiatry 2007;19:397–406.
  2. Sharma T, Antonova L: Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26:25–40.
  3. Snitz BE, Macdonald AW 3rd, Carter CS: Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179–194.
  4. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET: Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16–25.
  5. Toulopoulou T, Grech A, Morris RG, Schulze K, McDonald C, Chapple B, Rabe-Hesketh S, Murray RM: The relationship between volumetric brain changes and cognitive function: a family study on schizophrenia. Biol Psychiatry 2004;56:447–453.
  6. Antonova E, Sharma T, Morris R, Kumari V: The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res 2004;70:117–145.
  7. Seidman LJ, Faraone SV, Goldstein JM, Kremen WS, Horton NJ, Makris N, Toomey R, Kennedy D, Caviness VS, Tsuang MT: Left hippocampal volume as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric study of nonpsychotic first-degree relatives. Arch Gen Psychiatry 2002;59:839–849.
  8. Antonova E, Kumari V, Morris R, Halari R, Anilkumar A, Mehrotra R, Sharma T: The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol Psychiatry 2005;58:457–467.
  9. Salgado-Pineda P, Baeza I, Perez-Gomez M, Vendrell P, Junque C, Bargallo N, Bernardo M: Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. Neuroimage 2003;19:365–375.
  10. Krabbendam L, Marcelis M, Delespaul P, Jolles J, van Os J: Single or multiple familial cognitive risk factors in schizophrenia? Am J Med Genet 2001;105:183–188.
  11. Marcelis M, Suckling J, Hofman P, Woodruff P, Bullmore E, van Os J: Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia. Schizophr Res 2006;86:45–53.
  12. Marcelis M, Suckling J, Woodruff P, Hofman P, Bullmore E, van Os J: Searching for a structural endophenotype in psychosis using computational morphometry. Psychiatry Res 2003;122:153–167.
  13. Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J: Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 2005;58:105–110.
  14. Spitzer RL, Endicott J, Robbins E: Research Diagnostic Criteria (RDC) for a selected group of functional psychoses, ed 3. New York, Biometrics Research Division, 1978.
  15. Lukoff D, Nuechterlein KH, Ventura J: Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr Bull 1986;12:594–602.
  16. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr Bull 1987;13:261–276.
  17. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99–110.
  18. McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991;48:764–770.
  19. Annett M: A classification of hand preference by association analysis. Br J Psychol 1970;61:303–321.
  20. Smeets R, Dingemans P: Composite International Diagnostic Interview (CIDI). Geneva, World Health Organisation, 1993.
  21. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ: Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 1999;18:32–42.
  22. Suckling J, Brammer MJ, Lingford-Hughes A, Bullmore ET: Removal of extracerebral tissues in dual-echo magnetic resonance images via linear scale-space features. Magn Reson Imaging 1999;17:247–256.
  23. Suckling J, Sigmundsson T, Greenwood K, Bullmore ET: A modified fuzzy clustering algorithm for operating independent brain tissue classification of dual echo MR images. Magn Reson Imaging 1999;17:1065–1076.
  24. Cox RW: Analysis of Functional Neuroimages, version 1.01. Madison, College of Wisconsin, 1994.
  25. Brand N, Jolles J: Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985;112:201–210.
  26. Lezak MD: Neuropsychological Assessment. Oxford, Oxford University Press, 1995.
  27. Stroop JR: Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643–662.

    External Resources

  28. Houx PJ, Vreeling FW, Jolles J: Age-associated cognitive decline is related to biological life-events; in Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM (eds): Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Chichester, Wiley, 1991, pp 353–359.
  29. Reitan RM: Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills 1958;8:271–276.

    External Resources

  30. Stata Corp: STATA Statistical Software: Release 8.0. College Station, 2001.
  31. Goldstein H: Multilevel Models in Educational and Social Research. London, Griffin, 1987.
  32. Poline JB, Mazoyer BM: Analysis of individual positron emission tomography activation maps by detection of high signal-to-noise-ratio pixel clusters. J Cereb Blood Flow Metab 1993;13:425–437.
  33. Rabe-Hesketh S, Bullmore ET, Brammer MJ: The analysis of functional magnetic resonance images. Stat Methods Med Res 1997;6:215–237.
  34. Levitt JJ, McCarley RW, Dickey CC, Voglmaier MM, Niznikiewicz MA, Seidman LJ, Hirayasu Y, Ciszewski AA, Kikinis R, Jolesz FA, Shenton ME: MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. Am J Psychiatry 2002;159:1190–1197.
  35. Alexander GE, Crutcher MD, DeLong MR: Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, ‘prefrontal’ and ‘limbic’ functions. Prog Brain Res 1990;85:119–146.
  36. Graybiel AM: The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 2005;15:638–644.
  37. Laywer G, Nyman H, Agartz I, Arnborg S, Jonsson EG, Sedvall GC, Hall H: Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 2006;6:31.
  38. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC: Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999;156:1200–1204.
  39. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM: Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005;30:765–774.
  40. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998;155:1711–1717.
  41. Schmahmann JD, Sherman JC: Cerebellar cognitive affective syndrome. Int Rev Neurobiol 1997;41:433–440.
  42. Andreasen NC, Nopoulos P, O’Leary DS, Miller DD, Wassink T, Flaum M: Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry 1999;46:908–920.
  43. Andreasen NC, Paradiso S, O’Leary DS: ‘Cognitive dysmetria’ as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 1998;24:203–218.
  44. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC: Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Arch Gen Psychiatry 1993;50:541–550.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50